HALOZYME THERAPEUTICS, INC. (HALO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 325,719 | 264,861 | 290,084 | 231,353 |
| Selling, general and administrative | 41,614 | 42,362 | 41,241 | 35,711 |
| Research and development | 17,543 | 14,799 | 18,458 | 21,038 |
| Cost of sales | 46,359 | 48,403 | 49,426 | 39,607 |
| Amortization of intangibles | 17,762 | 17,762 | 17,762 | 17,762 |
| Total operating expenses | 123,278 | 123,326 | 126,887 | 114,118 |
| Operating income | 202,441 | 141,535 | 163,197 | 117,235 |
| Interest expense | 4,394 | 4,525 | 4,524 | 4,524 |
| Investment and other income, net | 6,891 | 6,818 | 6,474 | 5,032 |
| Income before income tax expense | 204,938 | 143,828 | 165,147 | 117,743 |
| Income tax expense | 39,778 | 25,733 | 28,136 | 24,498 |
| Net income | 165,160 | 118,095 | 137,011 | 93,245 |
| Basic (in shares) | 121,343,000 | 123,215,000 | 126,850,000 | 127,116,000 |
| Basic (usd per share) | 1.36 | 0.96 | 1.08 | 0.73 |
| Diluted (in shares) | 124,158,000 | 126,644,000 | 130,134,000 | 129,222,000 |
| Diluted (usd per share) | 1.33 | 0.93 | 1.05 | 0.72 |